These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27576609)

  • 1. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study.
    O'Reilly K; O'Connell P; Donohoe G; Coyle C; O'Sullivan D; Azvee Z; Maddock C; Sharma K; Sadi H; McMahon M; Kennedy HG
    Psychol Med; 2016 Nov; 46(15):3199-3211. PubMed ID: 27576609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
    Tsoutsoulas C; Mulsant BH; Kumar S; Ghazala Z; Voineskos AN; Menon M; Pollock BG; Rajji TK
    J Clin Psychiatry; 2017; 78(9):e1284-e1290. PubMed ID: 29188908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective observational cohort study of 'treatment as usual' over four years for patients with schizophrenia in a national forensic hospital.
    Richter MS; O'Reilly K; O'Sullivan D; O'Flynn P; Corvin A; Donohoe G; Coyle C; Davoren M; Higgins C; Byrne O; Nutley T; Nulty A; Sharma K; O'Connell P; Kennedy HG
    BMC Psychiatry; 2018 Sep; 18(1):289. PubMed ID: 30195335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia.
    Kim SJ; Jung D; Shim JC; Moon JJ; Jeon DW; Kim YN; Seo YS; Jung SS; Seo BJ; Kim JE
    Asian J Psychiatr; 2019 Dec; 46():111-117. PubMed ID: 31654923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive burden of anticholinergic medications in psychotic disorders.
    Eum S; Hill SK; Rubin LH; Carnahan RM; Reilly JL; Ivleva EI; Keedy SK; Tamminga CA; Pearlson GD; Clementz BA; Gershon ES; Keshavan MS; Keefe RSE; Sweeney JA; Bishop JR
    Schizophr Res; 2017 Dec; 190():129-135. PubMed ID: 28390849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Joshi YB; Thomas ML; Braff DL; Green MF; Gur RC; Gur RE; Nuechterlein KH; Stone WS; Greenwood TA; Lazzeroni LC; MacDonald LR; Molina JL; Nungaray JA; Radant AD; Silverman JM; Sprock J; Sugar CA; Tsuang DW; Tsuang MT; Turetsky BI; Swerdlow NR; Light GA
    Am J Psychiatry; 2021 Sep; 178(9):838-847. PubMed ID: 33985348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span.
    Khan WU; Ghazala Z; Brooks HJ; Subramaniam P; Mulsant BH; Kumar S; Voineskos AN; Blumberger DM; Kern RS; Rajji TK
    Schizophr Bull; 2021 Jan; 47(1):249-257. PubMed ID: 32619225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.
    Vinogradov S; Fisher M; Warm H; Holland C; Kirshner MA; Pollock BG
    Am J Psychiatry; 2009 Sep; 166(9):1055-62. PubMed ID: 19570929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
    Ang MS; Abdul Rashid NA; Lam M; Rapisarda A; Kraus M; Keefe RSE; Lee J
    J Clin Psychopharmacol; 2017 Dec; 37(6):651-656. PubMed ID: 29016375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients.
    Joshi YB; Thomas ML; Hochberger WC; Bismark AW; Treichler EBH; Molina J; Nungaray J; Cardoso L; Sprock J; Swerdlow NR; Light GA
    Schizophr Res; 2019 Jun; 208():384-389. PubMed ID: 30738698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.
    Pasina L; Djade CD; Lucca U; Nobili A; Tettamanti M; Franchi C; Salerno F; Corrao S; Marengoni A; Iorio A; Marcucci M; Violi F; Mannucci PM
    Drugs Aging; 2013 Feb; 30(2):103-12. PubMed ID: 23239364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia.
    Tsoutsoulas C; Mulsant BH; Kalache SM; Kumar S; Ghazala Z; Voineskos AN; Butters MA; Menon M; Rajji TK
    Schizophr Res; 2016 Feb; 170(2-3):330-5. PubMed ID: 26724896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia.
    Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
    BMC Psychiatry; 2023 Jan; 23(1):61. PubMed ID: 36694187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Associations Between Measures of Anti-cholinergic Burden and Adverse Clinical Outcomes.
    Hsu WH; Wen YW; Chen LK; Hsiao FY
    Ann Fam Med; 2017 Nov; 15(6):561-569. PubMed ID: 29133497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Ballesteros A; Sánchez Torres AM; López-Ilundáin J; Mezquida G; Lobo A; González-Pinto A; Pina-Camacho L; Corripio I; Vieta E; de la Serna E; Mané A; Bioque M; Moreno-Izco L; Espliego A; Lorente-Omeñaca R; Amoretti S; Bernardo M; Cuesta MJ;
    Psychol Med; 2021 Sep; 51(12):2044-2053. PubMed ID: 32326991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
    Fonseca AO; Berberian AA; de Meneses-Gaya C; Gadelha A; Vicente MO; Nuechterlein KH; Bressan RA; Lacerda ALT
    Schizophr Res; 2017 Jul; 185():148-153. PubMed ID: 28110814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties.
    Jędrasik-Styła M; Ciołkiewicz A; Styła R; Linke M; Parnowska D; Gruszka A; Denisiuk M; Jarema M; Green MF; Wichniak A
    Psychiatr Q; 2015 Sep; 86(3):435-47. PubMed ID: 25601030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study.
    Weichert I; Romero-Ortuno R; Tolonen J; Soe T; Lebus C; Choudhury S; Nadarajah CV; Nanayakkara P; Orrù M; Di Somma S;
    J Clin Pharm Ther; 2018 Oct; 43(5):682-694. PubMed ID: 29729025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.